%0 Journal Article
%T Immunotherapy in breast cancer
%A Nematollah Rostami
%A Zeinab Mazloumi
%A Fatemeh Aghamaleki
%A Sima Rad
%A Abolfazl Movafagh
%A Mojgan Sheikhpour
%J Clinical Cancer Investigation Journal
%@ 2278-0513
%D 2019
%V 8
%N 4
%R 10.4103/ccij.ccij_45_19
%P 139-143
%X 
Over the last few years, the developments around cancer immunotherapy have led to a paradigm shift in the treatment of many different cancers and leukemias, in particular, melanoma, renal, bladder, and lung cancers with a remarkable impact on response rate and most importantly, overall survival was noticed. Breast cancer is most commonly considered to be a “noninflamed” cancer, and hence, this shift has been less marked within its treatment. However, some subsets of breast cancer, most notably triple-negative breast cancer, are deemed to be more “inflamed” and therefore may prove to be an appropriate cohort for immunotherapy.

%U https://ccij-online.org/article/immunotherapy-in-breast-cancer-800